journal article·2025-09-24

Wound Dressing Cryogel Materials Based on Poly(vinyl alcohol), Hyaluronic Acid, and Ag2O Nanoparticles

Valeriy Demchenko, Yevgen Mamunya, Illia Sytnyk, Maksym Iurzhenko, Nataliia Rybalchenko, Svitlana Zahorodnia, Olena Demchenko, Stanislav Rushkovsky, Dmytro Kunytskyi, Donghu Zeng, Viktoriia Talaniuk, Marta Musioł

ACS Applied Materials & Interfaces· Volume 17· Issue 38
Publisher page

Abstract

Hydrogel materials based on poly(vinyl alcohol) (PVA) and silver nanoparticles are used as wound dressings. However, chemical reducing agents, ultraviolet irradiation, and radiation irradiation are mainly used to reduce silver ions to nanoparticles in hydrogel dressings. In this study, polymeric cryogel materials based on poly(vinyl alcohol), hyaluronic acid (HA), and Ag 2 O nanoparticles were synthesized by reducing silver ions with hyaluronic acid followed by freezing and thawing of the samples. Structural features, thermophysical, mechanical, antimicrobial, cytotoxic and genotoxic properties of PVA-Ag-HA polymeric cryogel materials were studied by wide-angle X-ray scattering (WAXS), differential scanning calorimetry (DSC), thermogravimetric analysis (TGA), mechanical tests, antimicrobial, cytotoxic and genotoxic studies. Studies of cryogel materials using wide-angle X-ray scattering showed that the PVA-HA composite has a higher degree of crystallinity compared to the pure PVA. It was found that during the formation of samples, silver ions are reduced in the polymer systems PVA-HA-Ag + at T = 85 °C, within 1 h with the formation of Ag 2 O nanoparticles. The addition of hyaluronic acid to the composition of PVA cryogel increases the water absorption of the samples, and a decrease in the freezing time and concentration of nanoparticles leads to an increase in the water absorption of PVA-HA cryogel materials. The thermal stability of all the studied samples, except HA, practically does not change up to a temperature of 200 °C. For the studied cryogel materials, the tensile strength increases with increasing freezing time and concentration of Ag 2 O nanoparticles up to 0.5 wt %. PVA-HA-Ag 2 O cryogel nanocomposites exhibited antimicrobial activity against Staphylococcus aureus, Staphylococcus epidermidis, and Escherichia coli at silver oxide nanoparticle concentrations of ≥0.05 wt %. The obtained nanocomposites with low concentrations of Ag 2 O nanoparticles were not toxic. They did not inhibit the viability of MDCK and L-929 cell cultures at silver oxide nanoparticle concentrations of ≥0.1 wt %. When studying the genotoxic properties of cryogel materials, no mutagenic and clastogenic activity was detected. The obtained materials have potential applications for the creation of dressings for the treatment of wounds of various infectious nature.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Hydrogels: synthesis, properties, applications · Polymer Nanocomposite Synthesis and Irradiation · Electrospun Nanofibers in Biomedical Applications

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

E.O. Paton Electric Welding Institute

The National Academy of Sciences of Ukraine

International Polish-Ukrainian Research Laboratory ADPOLCOM

Zabolotny Institute of Microbiology and Virology

National Research Center for Radiation Medicine, Hematology and Oncology

The National Academy of Medical Sciences of Ukraine

Taras Shevchenko National University of Kyiv

Centre of Polymer and Carbon Materials

The Polish Academy of Sciences

Funding

National Research Foundation of Ukraine

References (53)

Show source-provided references
1. 10.1002/adfm.20190097110.1002/adfm.201900971 ↗
2. 10.1007/s40204-014-0026-710.1007/s40204-014-0026-7 ↗
3. 10.1021/mz300451r10.1021/mz300451r ↗
4. 10.1039/b922220k10.1039/b922220k ↗
5. 10.1021/acsami.6b0562710.1021/acsami.6b05627 ↗
6. 10.1021/acs.macromol.6b0153910.1021/acs.macromol.6b01539 ↗
7. 10.1016/j.ijbiomac.2021.08.00210.1016/j.ijbiomac.2021.08.002 ↗
8. 10.1155/2021/222542610.1155/2021/2225426 ↗
9. 10.1016/j.jmbbm.2015.11.02110.1016/j.jmbbm.2015.11.021 ↗
10. 10.3390/polym1413256010.3390/polym14132560 ↗
11. 10.1021/acs.molpharmaceut.9b0102010.1021/acs.molpharmaceut.9b01020 ↗
12. 10.1080/15567036.2018.149578610.1080/15567036.2018.1495786 ↗
13. 10.1016/s0169-409x(01)00239-310.1016/s0169-409x(01)00239-3 ↗
14. 10.1080/1023666X.2018.155856710.1080/1023666X.2018.1558567 ↗
15. 10.1016/j.biomaterials.2012.01.04810.1016/j.biomaterials.2012.01.048 ↗
16. 10.1080/00914037.2019.170651010.1080/00914037.2019.1706510 ↗
17. Singh G. · J. Fundam. Pharm. Res. · 2014 · 2 · 35
18. 10.30476/tips.2019.81604.100210.30476/tips.2019.81604.1002 ↗
19. 10.1007/s10853-015-9382-510.1007/s10853-015-9382-5 ↗
20. 10.1021/acsabm.2c0003410.1021/acsabm.2c00034 ↗
21. 10.1007/s13204-020-01368-010.1007/s13204-020-01368-0 ↗
22. 10.1016/j.carbpol.2020.11643110.1016/j.carbpol.2020.116431 ↗
23. 10.1016/j.arabjc.2014.07.00510.1016/j.arabjc.2014.07.005 ↗
24. 10.1016/j.carbpol.2018.12.02110.1016/j.carbpol.2018.12.021 ↗
25. 10.1016/j.ijbiomac.2018.11.25210.1016/j.ijbiomac.2018.11.252 ↗
26. 10.1080/00222348.2019.170971410.1080/00222348.2019.1709714 ↗
27. Bahram M. · 2016
28. 10.1080/00222348.2019.161568810.1080/00222348.2019.1615688 ↗
29. 10.1016/j.ijbiomac.2018.04.01010.1016/j.ijbiomac.2018.04.010 ↗
30. 10.1016/S1369-7021(10)70202-910.1016/S1369-7021(10)70202-9 ↗
31. 10.1021/ma990758710.1021/ma9907587 ↗
32. 10.1016/j.radphyschem.2019.10836910.1016/j.radphyschem.2019.108369 ↗
33. 10.3390/pharmaceutics1309146110.3390/pharmaceutics13091461 ↗
34. 10.1016/j.ijbiomac.2020.02.04810.1016/j.ijbiomac.2020.02.048 ↗
35. 10.1007/s12668-016-0220-210.1007/s12668-016-0220-2 ↗
36. 10.3390/polym1205116710.3390/polym12051167 ↗
37. Case C. L. · 1984
38. 10.15407/microbiolj86.06.03010.15407/microbiolj86.06.030 ↗
39. 10.1101/pdb.prot08737910.1101/pdb.prot087379 ↗
40. 10.1016/S1383-5718(01)00255-810.1016/S1383-5718(01)00255-8 ↗
41. 10.1134/S156009041406004910.1134/S1560090414060049 ↗
42. 10.1038/s41598-019-46061-710.1038/s41598-019-46061-7 ↗
43. 10.1134/S0965545X1505006510.1134/S0965545X15050065 ↗
44. 10.3390/pharmaceutics1402044110.3390/pharmaceutics14020441 ↗
45. 10.1016/j.polymer.2019.03.04010.1016/j.polymer.2019.03.040 ↗
46. 10.1016/j.jddst.2020.10211110.1016/j.jddst.2020.102111 ↗
47. 10.3103/S036152190701010710.3103/S0361521907010107 ↗
48. 10.33380/2305-2066-2020-9-4-136-14010.33380/2305-2066-2020-9-4-136-140 ↗
49. 10.17221/1930-VETMED10.17221/1930-VETMED ↗
50. Agayants I. M. · Vestnik MITCHT · 2014 · 9 · 42
51. 10.1038/s41598-024-53782-x10.1038/s41598-024-53782-x ↗
52. 10.47723/kcmj.v14i1.2310.47723/kcmj.v14i1.23 ↗
53. DINENISO 10993-5:2009 · 2022